- Home
- WIT vs BIIB Comparison
WIT vs BIIB Comparison
Compare WIT & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WIT | BIIB |
|---|---|---|
| Founded | 1945 | 1978 |
| Country | India | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8B | 27.1B |
| IPO Year | 2000 | 1996 |
Fundamental Metrics
Financial Performance| Metric | WIT | BIIB |
|---|---|---|
| Price | $2.26 | $183.32 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 27 |
| Target Price | N/A | ★ $194.72 |
| AVG Volume (30 Days) | ★ 15.5M | 827.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.76% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 8.79 |
| Revenue | N/A | ★ $9,890,600,000.00 |
| Revenue This Year | $6.75 | N/A |
| Revenue Next Year | $6.67 | N/A |
| P/E Ratio | ★ $16.59 | $21.03 |
| Revenue Growth | N/A | ★ 2.22 |
| 52 Week Low | $2.11 | $110.04 |
| 52 Week High | $3.18 | $202.41 |
Technical Indicators
Market Signals| Indicator | WIT | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 44.83 | 46.95 |
| Support Level | $2.11 | $181.24 |
| Resistance Level | $2.88 | $186.17 |
| Average True Range (ATR) | 0.09 | 5.30 |
| MACD | 0.03 | -1.14 |
| Stochastic Oscillator | 34.44 | 16.93 |
Price Performance
Historical ComparisonAbout WIT Wipro Limited
Wipro is a multinational IT services provider based in Bengaluru, India. The company pivoted into the IT space in the 1980s and grew into one of the largest Indian IT consulting companies during the dot-com boom. Nowadays, Wipro leverages its offshore outsourcing model to derive a significant portion of its revenue from North America and Europe.
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).